Preclinical development of plant‐based oral immune modulatory therapy for haemophilia B
Preclinical development of plant‐based oral immune modulatory therapy for haemophilia B
About this item
Full title
Author / Creator
Publisher
England: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
England: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Summary
Anti‐drug antibody (ADA) formation is a major complication in treatment of the X‐linked bleeding disorder haemophilia B (deficiency in coagulation factor IX, FIX). Current clinical immune tolerance protocols are often not effective due to complications such as anaphylactic reactions against FIX. Plant‐based oral tolerance induction may a...
Alternative Titles
Full title
Preclinical development of plant‐based oral immune modulatory therapy for haemophilia B
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8486253
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8486253
Other Identifiers
ISSN
1467-7644
E-ISSN
1467-7652
DOI
10.1111/pbi.13608
